APA (7th ed.) Citation

C, N., J, H., H, K., T, T., Y, Y., S, K., . . . A, H. (2026). Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma. International journal of clinical oncology. https://doi.org/10.1007/s10147-026-03142-8

Chicago Style (17th ed.) Citation

C, Nitani, et al. "Efficacy of Anti-GD2 Antibody Immunotherapy with Filgrastim and Teceleukin Versus Standard Treatment with Sargramostim, Aldesleukin and Isotretinoin in Children with High-risk Neuroblastoma." International Journal of Clinical Oncology 2026. https://doi.org/10.1007/s10147-026-03142-8.

MLA (9th ed.) Citation

C, Nitani, et al. "Efficacy of Anti-GD2 Antibody Immunotherapy with Filgrastim and Teceleukin Versus Standard Treatment with Sargramostim, Aldesleukin and Isotretinoin in Children with High-risk Neuroblastoma." International Journal of Clinical Oncology, 2026, https://doi.org/10.1007/s10147-026-03142-8.